Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 11/20 | 0.59 |
| ▸ | AXL | P30530 | 2/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.58 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 2/20 | 0.48 |
| ▸ | PLK4 | O00444 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | INSR | P06213 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | ROS1 | P08922 | 2/20 | 0.48 |
| ▸ | FER | P16591 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831501 | 0.79 | CDK8 (0.81) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL14365352 | 0.79 | CDK8 (0.47) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL14365331 | 0.75 | CDK8 (0.55) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL29569140 | 0.75 | PDGFRB (0.55) | CDK8PDGFRBPDGFRACHEK2CHEK1 | |
| SCHEMBL13917340 | 0.75 | PDGFRB (0.55) | CDK8PDGFRBPDGFRACHEK2CHEK1 | |
| SCHEMBL410704 | 0.75 | CDK8 (1.00) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL858420 | 0.75 | CDK8 (0.59) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL858281 | 0.74 | CDK8 (0.54) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL16186619 | 0.74 | CDK8 (0.58) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL416750 | 0.73 | PIK3CA (1.00) | CDK8AXLPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| EP-1696920-B1 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7291630-B2 | Azaindoles as inhibitors of c-Jun N-terminal kinases | EISAI CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291630-B2 | Azaindoles as inhibitors of c-Jun N-terminal kinases | EISAI CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060235042-A1 | Synthesis | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885AXL 1354/4885PIK3CD 139/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885AXL 1354/4885PIK3CD 139/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885AXL 1354/4885PIK3CD 139/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885AXL 1354/4885PIK3CD 139/4885 |
| US-20060235042-A1 | Synthesis | AZI2, CYP3A5, CYP3A7 | CDK8 422/4885AXL 4652/4885PIK3CD 1329/4885 |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | RET, GFRA1, GFRA3 | CDK8 2155/4885AXL 73/4885PIK3CD 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.